Surmodics, Inc. (SRDX) News
Filter SRDX News Items
SRDX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SRDX News Highlights
- SRDX's 30 day story count now stands at 2.
- Over the past 2 days, the trend for SRDX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest SRDX News From Around the Web
Below are the latest news stories about SURMODICS INC that investors may wish to consider to help them evaluate SRDX as an investment opportunity.
SurModics (SRDX) Soars 6.2%: Is Further Upside Left in the Stock?SurModics (SRDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
Here's Why You Should Retain Surmodics (SRDX) Stock for NowSurmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock. |
Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH SymposiumEDEN PRAIRIE, Minn., November 16, 2023--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial was presented by Dr. Peter A. Schneider at the 50th Annual VEITH Symposium in New York, New York. |
Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposiumEDEN PRAIRIE, Minn., November 16, 2023--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that 24-month data from the SWING Trial, a first-in-human study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon (DCB) was presented at the 50th annual VEITH Symposium in New York, New York. |
Surmodics, Inc.'s (NASDAQ:SRDX) Intrinsic Value Is Potentially 91% Above Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, Surmodics fair value estimate is US$66.09 Surmodics' US$34.64... |
Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28EDEN PRAIRIE, Minn., November 14, 2023--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the 35th Annual Piper Sandler Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY from November 28-30, 2023. Management will present on Tuesday, November 28, at 8:30 a.m. ET (7:30 a.m. CT). |
Surmodics, Inc. (NASDAQ:SRDX) Q4 2023 Earnings Call TranscriptSurmodics, Inc. (NASDAQ:SRDX) Q4 2023 Earnings Call Transcript November 10, 2023 Operator: Welcome everyone to Surmodics Fourth Quarter and Fiscal Year 2023 Earnings Call. Please note that this call is being webcast. The webcast is accessible through the Investor Relations section of the Surmodics website at www.surmodics.com, where an audio replay will be archived for […] |
2 Highly Ranked Medical Stocks to Consider After Healthy Quarterly ResultsAfter impressive quarterly results on Wednesday, here are two highly-ranked Zacks Medical sector stocks that investors may want to consider. |
Surmodics (SRDX) Q4 Earnings Top Estimates, Revenues Up Y/YSurmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust segmental revenues. |
Q4 2023 Surmodics Inc Earnings CallQ4 2023 Surmodics Inc Earnings Call |